Menu
Search
|

Menu

Close
X

Quanterix Corp QTRX.OQ (NASDAQ Stock Exchange Global Market)

16.30 USD
+0.55 (+3.49%)
As of 1:30 AM IST
chart
Previous Close 15.75
Open 15.76
Volume 17,850
3m Avg Volume 32,906
Today’s High 16.58
Today’s Low 15.76
52 Week High 24.61
52 Week Low 13.55
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
8
FY17
18
FY16
18
EPS (USD)
FY18
-0.331
FY17
-1.814
FY16
-1.364
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.84
LT Debt to Equity (MRQ)
vs sector
--
12.51
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Kevin Hrusovsky
Executive Chairman of the Board, President, Chief Executive Officer, Since 2015
Salary: $411,000.00
Bonus: $137,500.00
Joseph Driscoll
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
David Duffy
Senior Vice President, Research & Development and Chief Technology Officer, Since 2013
Salary: --
Bonus: --
Ernest Orticerio
Senior Vice President - Finance and Corporate Development, Since 2017
Salary: --
Bonus: --
Mark Roskey
Senior Vice President and General Manager of Applications and Reagents, Since 2014
Salary: $236,812.00
Bonus: $82,884.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

113 Hartwell Ave
LEXINGTON   MA   02421-3125

Phone: +1617.3019400

Quanterix Corporation develops ultra-sensitive digital immunoassay platform and tools for life science research and diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to detect protein biomarkers. The Company is also focusing to enable and develop novel therapies and diagnostics to facilitate in healthcare for earlier detection, monitoring, prognosis and, ultimately, prevention of disease. Simoa focuses on research and clinical testing applications and significantly advances enzyme-linked immunosorbent assay (ELISA) technology which is capable of unprecedented protein detection sensitivity. It also focuses on research and diagnostics for brain injuries, heart disease, cancer and other infectious diseases with its technology. The Company offers Simoa HD-1 analyzer, which is an automated immunoassay platform with multiplexing and custom assay capability.

SPONSORED STORIES